Corium International, Inc. CORI was a big mover last session, as its shares rose almost 10% on the day. The rally came on the back of the receipt of favorable feedback from the FDA on the company’s pre-investigational New Drug Application submission for once-weekly transdermal Corplex Donepezil. This also led to far more shares changing hands than in a normal session. Yesterday’s rally breaks the recent trend for the company, as the stock is now trading above the volatile price range of $3.96 to $4.80 in the past one-month time frame. Over the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future. Corium International currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%. A better-ranked med-generic drug stock is Amphastar Pharmaceuticals, Inc. AMPH with a Zacks Rank #1 (Strong Buy). Is CORI going up? Or down? Predict to see what others think: Up or Down Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AMPHASTAR PHARM (AMPH): Free Stock Analysis Report CORIUM INTRNTNL (CORI): Free Stock Analysis Report To read this article on Zacks.com click here.